Quantification of Candesartan in Mouse Plasma by MALDI-TOFMS and in Tissue Sections by MALDI-Imaging Using the Stable-Isotope Dilution Technique
- PMID: 24860711
- PMCID: PMC3967012
- DOI: 10.5702/massspectrometry.A0021
Quantification of Candesartan in Mouse Plasma by MALDI-TOFMS and in Tissue Sections by MALDI-Imaging Using the Stable-Isotope Dilution Technique
Abstract
To determine the contents of candesartan in mouse plasma, and blood vessel and kidney sliced sections and also better understand its pharmacokinetics, we applied matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOFMS) and MALDI-imaging mass spectrometry (IMS) with the selected reaction monitoring (SRM) mode using a labeled-internal standard. The results of fundamental examinations showed that the slope of the resulting curves of candesartan in the plasma from the equation was 0.91 and the y-intercept was 0.02. Both intra- and inter-day accuracies (n=10) and the precision of candesartan in the plasma by MALDI-TOFMS with the SRM mode were in the range of 3.4 to 17.3% and 93.2%, respectively. The detection limit of candesartan in spiked plasma was 0.2 nmol/L. IMS analysis enabled us to clarify distinct spacial time-distribution images in sliced mouse blood vessel and kidney sections although it still needed to improve a protocol of quantification. Typical pharmacokinetic patterns of candesartan were obtained in the plasma and sliced kidney sections, but those in the blood vessel sections gradually increased 24 h after administration. MALDI-TOFMS and IMS with the SRM mode are powerful tools to identify the spacial distribution and traceability of candesartan in sliced blood vessel and tissue sections as well as in the plasma.
Keywords: MALDI-imaging; candesartan; pharmacokinetics; spacial localization; stable-isotope dilution technique.
Figures




Similar articles
-
Quantitative mass barcode-like image of nicotine in single longitudinally sliced hair sections from long-term smokers by matrix-assisted laser desorption time-of-flight mass spectrometry imaging.J Anal Toxicol. 2014 Jul-Aug;38(6):349-53. doi: 10.1093/jat/bku032. Epub 2014 May 6. J Anal Toxicol. 2014. PMID: 24802158
-
Exploring three-dimensional matrix-assisted laser desorption/ionization imaging mass spectrometry data: three-dimensional spatial segmentation of mouse kidney.Anal Chem. 2012 Jul 17;84(14):6079-87. doi: 10.1021/ac300673y. Epub 2012 Jul 5. Anal Chem. 2012. PMID: 22720760
-
Matrix-assisted laser desorption/ionization imaging mass spectrometry of intraperitoneally injected danegaptide (ZP1609) for treatment of stroke-reperfusion injury in mice.Rapid Commun Mass Spectrom. 2018 Jun 30;32(12):951-958. doi: 10.1002/rcm.8115. Rapid Commun Mass Spectrom. 2018. PMID: 29575411
-
Applications of stable isotopes in MALDI imaging: current approaches and an eye on the future.Anal Bioanal Chem. 2021 Apr;413(10):2637-2653. doi: 10.1007/s00216-021-03189-8. Epub 2021 Feb 2. Anal Bioanal Chem. 2021. PMID: 33532914 Review.
-
[New Progress of MALDI-TOF-IMS in the Study of Proteomics].Fa Yi Xue Za Zhi. 2016 Apr;32(2):126-30. Fa Yi Xue Za Zhi. 2016. PMID: 27501686 Review. Chinese.
Cited by
-
Comparison of the relative importance of vascular and plasma drug concentrations to the hypotensive effect of telmisartan in rats.J Renin Angiotensin Aldosterone Syst. 2016 Mar 23;17(1):1470320316633895. doi: 10.1177/1470320316633895. Print 2016 Jan-Mar. J Renin Angiotensin Aldosterone Syst. 2016. PMID: 27009286 Free PMC article.
-
Absolute Quantitative MALDI Imaging Mass Spectrometry: A Case of Rifampicin in Liver Tissues.Anal Chem. 2016 Feb 16;88(4):2392-8. doi: 10.1021/acs.analchem.5b04409. Epub 2016 Feb 5. Anal Chem. 2016. PMID: 26814665 Free PMC article.
-
A binary matrix for the rapid detection and characterization of small-molecule cardiovascular drugs by MALDI-MS and MS/MS.Anal Methods. 2018;10:572-578. doi: 10.1039/C7AY02583A. Epub 2018 Feb 1. Anal Methods. 2018. PMID: 30319716 Free PMC article.
References
-
- 1) A. Joost, H. C. Schunkert, P. W. Radke. Candesartan cilexetil: An update. Expert Opin. Pharmacother. 12: 1769–1780, 2011 - PubMed
-
- 2) K. J. McClellan, K. L. Goa. Candesartan cilexetil: A review of its use in essential hypertension. Drugs 56: 847–869, 1998 - PubMed
-
- 3) I. Meineke, H. Feltkamp, A. Högemann, U. Gundert-Remy. Pharmacokinetics and pharmacodynamics of candesartan after administration of its pro-drug candesartan cilexetil in patients with mild to moderate essential hypertension: A population analysis. Eur. J. Clin. Pharmacol. 53: 221–228, 1997. - PubMed
-
- 4) A. Himmelmann, S. Keinänen-Kiukaanniemi, A. Wester, J. Redón, R. Asmar, T. Hedner; Effect Study Group. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. Blood Press. 10: 43–51, 2001 - PubMed
-
- 5) H. Buter, G. Y. Navis, A. J. Woittiez, D. de Zeeuw, P. E. de Jong. Pharmacokinetics and pharmacodynamics of candesartan cilexetil in patients with normal to severely impaired renal function. Eur. J. Clin. Pharmacol. 54: 953–958, 1999 - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources